Musculoskeletal Tumor Center

  • Meet the Team

    The Musculoskeletal Tumor Center is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.

  • Show All

    Oncology

    A photo of James Geller, MD.

    James I. Geller, MD
    Medical Director, Kidney and Liver Tumors Program

    513-636-4266

    james.geller@cchmc.org

    James I. Geller, MD

    Medical Director, Kidney and Liver Tumors Program

    Co-Medical Director, Retinoblastoma Program

    Associate Director, Global Cancer Programs

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: james.geller@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology

    Research Interests

    Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics

    Biography

    James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of associate professor of pediatrics.

    Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare/Retinoblastoma Committee as both a Steering/Voting Member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as Steering/Voting Member, RTC Sub-Committee Chair of Developmental Therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.

    Education and Training

    MD: Sackler School of Medicine, 1997.

    Residency: New York Medical College, 2000.

    Fellowship: St Jude Children's Research Hospital, 2004.

    Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.

    Publications

    View PubMed Publications

    Grants

    Identification, selection, and validation of rationale molecular targets that result from this High-Risk Wilms ‘TARGET’ initiative. National Institutes of Health. 2009 - 2011.
    A photo of Rajaram Nagarajan, MD.

    Rajaram Nagarajan, MD, MS
    Associate Director, Oncology Clinical Operations

    513-636-0670

    rajaram.nagarajan@cchmc.org

    Rajaram Nagarajan, MD, MS

    Associate Director, Oncology Clinical Operations

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-0670

    Fax: 513-636-3549

    Email: rajaram.nagarajan@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Bone tumors; late effects of pediatric cancer therapy

    Research Interests

    Outcomes following cancer therapy and bone sarcomas

    Education and Training

    BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.

    MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.

    Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.

    Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.

    MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.

    Certifications: Pediatrics, Pediatric Hematology / Oncology.

    Publications

    View PubMed Publications

    A photo of Dr. Perentesis.

    John P. Perentesis, MD, FAAP
    Director, Division of Oncology and Cancer Programs

    513-636-8241

    john.perentesis@cchmc.org

    A photo of Dr. Perentesis.

    John P. Perentesis, MD, FAAP

    Director, Division of Oncology and Cancer Programs

    Deb Kleisinger Endowed Chair of Novel Cancer Treatments

    Executive Co-Director, Cancer and Blood Diseases Institute

    Director, Leukemia / Lymphoma Program

    Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)

    Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium

    Professor, UC Department of Pediatrics

    Phone: 513-636-8241

    Email: john.perentesis@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials

    Research Interests

    Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development

    Biography

    John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.

    In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.

    Education and Training

    MD: University of Michigan, Ann Arbor, MI, 1980.

    Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.

    Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.

    Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.

    Certification: Pediatrics, 1989; Hematology/Oncology, 1990.

    Publications

    View PubMed Publications

    Grants

    The Children's Oncology Group Chair Grant. Site Principal Investigator. National Institutes of Health. Mar 2008 - Mar 2013. #U10 CA 098543.

    Children's Oncology Group Phase I. Site Principal Investigator. National Institutes of Health. Aug 2002 - Jul 2012. #U01 CA 097452.

    Children's Oncology Group New Publication Committee. National Institutes of Health. Sep 2006 - Jul 2012. #U01 CA 97542 .

    Cincinnati Children's Hyundai Scholar in Childhood Cancer Drug Development. Hyundai Hope on Wheels. Oct 2010 - Oct 2011.

    A photo of Brian Weiss.

    Brian D. Weiss, MD
    Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute

    513-636-9863

    brian.weiss@cchmc.org

    Brian D. Weiss, MD

    Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute

    Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium

    Medical Director, Neuroblastoma Program

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-9863

    Fax: 513-636-3549

    Email: brian.weiss@cchmc.org

    Show All

    Specialties

    Targeted agents for neurofibromatosis type 1-related malignancies; high-risk neuroblastoma and 131I-MIBG treatment of neuroblastoma; new approaches to targeting and killing neuroblastoma cells

    Education and Training

    MD: Northwestern University Medical School, Chicago, IL, 1993.

    Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

    Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

    Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007

    Publications

    View PubMed Publications

    Grants

    Children's Oncology Group Chairs Grant. National Institutes of Health (Children's Oncology Group)
    U10 CA 098543 Mar 2011 - Feb 2012.

    Bone Marrow Transplantation

    A photo of Stella Davies.

    Stella M. Davies, MBBS, PhD, MRCP
    Director, Bone Marrow Transplantation and Immune Deficiency

    513-636-2469

    stella.davies@cchmc.org

    Stella M. Davies, MBBS, PhD, MRCP

    Director, Bone Marrow Transplantation and Immune Deficiency

    Jacob G. Schmidlapp Endowed Chair

    Professor, UC Department of Pediatrics

    Phone: 513-636-2469

    Fax: 513-636-3549

    Email: stella.davies@cchmc.org

    Show All

    Specialties

    Education and Training

    MBBS: University of Newcastle-Upon-Tyne, England, 1981.

    Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.

    PhD: University of Newcastle-Upon-Tyne, England, 1989.

    Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.

    Publications

    View PubMed Publications

    Sonata Jodele

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-1565

    Fax: 513-636-3549

    Email: sonata.jodele@cchmc.org

    Show All

    Specialties

    Bone marrow transplantation

    Education and Training

    MD: Vilnius University School of Medicine, 1988-1994.

    Residency: Pediatrics, Downstate HSC at Brooklyn, Brooklyn, NY, 1998-2001.

    Fellowship: Pediatric Hematology Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.

    Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.

    Licenses: California, 2001-present; Ohio, 2004-present.

    Publications

    View PubMed Publications

    Orthopaedic Surgery

    A photo of Joel Sorger.

    Joel I. Sorger, MD
    Director, Division of Musculoskeletal Tumor Center and Pediatric Joint Replacement Surgery

    513-636-4787

    joel.sorger@cchmc.org

    Joel I. Sorger, MD

    Director, Division of Musculoskeletal Tumor Center and Pediatric Joint Replacement Surgery

    Assistant Professor, Division of Pediatric Surgery

    Phone: 513-636-4787

    Fax: 513-636-3928

    Email: joel.sorger@cchmc.org

    Show All

    Specialties

    Orthopaedic oncology; joint replacement surgery

    Education and Training

    BS: Biology, University of Richmond, Virginia, August 1983-May 1987.

    MD: Medical College of Virginia: Richmond, Virginia, August 1987-May 1991.

    Intern: General Surgery Intern, University of Cincinnati: Cincinnati, Ohio,
    July 1991-June 1992.

    Residency: General surgery resident, University of Cincinnati College of Medicine; Orthopaedic surgery resident, University of Cincinnati College of Medicine.

    Fellowship: Management and Treatment of Bone and Soft Tissue Sarcomas, Harvard University: Massachusetts General Hospital and Boston, Children’s Hospital, Orthopaedic Oncology Fellowship, August 1998-July 1999; Orthopaedic research fellow, Noyes-Giannestras Biomechanics Lab, University of Cincinnati Department of Aerospace Engineering.

    Certification: American Board of Orthopaedic Surgeons.

    Publications

    View PubMed Publications

    Researchers

    Rachid Drissi, PhD

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: rachid.drissi@cchmc.org

    Show All

    Education and Training

    BS: University of Rouen, France, 1983.

    MS: University of Rouen, France, 1984.

    MS: University of Paris VI, France, 1988.

    PhD: University of Paris VI, France, 1994.

    Publications

    View PubMed Publications

    Joseph S. Palumbo, MD

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: joe.palumbo@cchmc.org

    Show All

    Specialties

    Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis

    Education and Training

    MD: Pennsylvania State University College of Medicine, Hershey, PA, 1993. 

    Residency: Childrens Hospital Medical Center, Cincinnati, OH, 1997. 

    Fellowship: Childrens Hospital Medical Center, Cincinnati, OH, 2000.

    Subspecialty: Pediatric Hematology / Oncology.

    Publications

    View PubMed Publications

    Grants

    Mechanisms Linking Metastasis to Tumor Procoagulant and Innate Immunity. Principal Investigator. National Institutes of Health. Jul 2006 - Jun 2012. #R01HL085545.

    Dao Pan, PhD

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-6315

    Fax: 513-636-1330

    Email: Dao.Pan@cchmc.org

    Show All

    Specialties

    Hematopoietic stem cells; Mesenchymal stem/progenitor cells; Gene therapy; Human genetics; Translational research; Lysosomal storage diseases

    Visit the Pan Lab.

    Education and Training

    PhD: University of Minnesota, Minneapolis, MN, 1997.

    MS: Peking Normal University, Beijing, China, 1991.

    BS: Peking Normal University, Beijing, China, 1988.

    Publications

    View PubMed Publications

    Grants

    Comprehensive Sickle Cell Center. Co-investigator. National Heart, Lung, and Blood Institute. Apr 2008 - Mar 2013. #U54 HL070871.

    Genetic Therapy for CNS Manifestations in MPS I via BBB-Targeted Protein Delivery. Principal Investigator. National Institute of Neurological Disorders and Stroke. Sep 2008 - Aug 2013. #R01 NS064330.

    Gaucher Disease: Treatment of Neurodegenerative Disease. Principal Investigator. National Institute of Neurological Disorders and Stroke. Sep 2013 - May 2018. #R01 NS086134.

    A photo of Nancy Ratner.

    Nancy Ratner, PhD
    Beatrice C. Lampkin Chair, Cancer Biology

    513-636-9469

    nancy.ratner@cchmc.org

    Nancy Ratner, PhD

    Beatrice C. Lampkin Chair, Cancer Biology

    Professor, UC Department of Pediatrics

    Phone: 513-636-9469

    Fax: 513-636-3549

    Email: nancy.ratner@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Development of the nervous system; peripheral nerve tumor formation

    Research Interests

    Genetic mutations in tumor suppressor genes

    Visit the Ratner Lab.

    Biography

    Dr. Nancy Ratner PhD,  is interested in understanding mechanisms of peripheral nerve tumor (neurofibroma) formation in Neurofibromatosis type 1 (NF1), a common inherited disorder in which children are predisposed to cancer of the nervous system, to learning problems, bone disorders, and other cancers. She identified EGFR as a potential therapeutic target in NF1 peripheral nerve tumorigenesis, and has developed cell culture and mouse models of NF1 nerve tumorigenesis. Her laboratory has also used analysis of gene expression to identify critical genes in neurofibroma and their malignant derivatives, MPNST. 

    Dr. Ratner received her bachelor's from Brown University, her doctorate from Indiana University, and was a postdoctoral fellow at Washington University in St. Louis. She was a member of the faculty at the University of Cincinnati from 1987 -  2004. Dr. Ratner is currently a professor in the Department of Pediatrics, Cincinnati Children’s Hospital, University of Cincinnati, and the program leader for Cancer Biology and Neural Tumors Program in the Cancer and Blood Disorders Institute where she holds the Beatrice C. Lampkin Endowed Chair in Cancer Biology and serves as PI of the NINDS P50 “Cincinnati Center in NF Research”. 

    Dr. Ratner is an active member of the International Consortium on the Molecular Biology of NF1, NF2, and schwannomatosis and was a member of the advisory board for the National Neurofibromatosis Foundation (now Children’s Tumor Foundation) from 1989 – 2007. She chaired the Department of Defense Neurofibromatosis Research Program Integration Panel in 2008, and currently serves as a member of the James McDonnell Brain Tumor Research Advisory Board. She received the von Recklinghausen Award from the Children’s Tumor Foundation in 2010.

    Education and Training

    PhD: Indiana University, 1982.

    BA: Brown University, 1975.

    Fellowship: Washington University St. Louis, 1982-1987.

    Publications

    View PubMed Publications

    Grants

    NIH-R01 NS 28840-20, "Mitogenic Activities in Neurofibromatosis", 9/2011 - 9/2016 (Ratner, PI)

    NIH-R01 CA118032-04, "Schwann cells in Neurofibromatosis type 2", 7/2007 - 6/2012 (Ratner, PI)

    NIH-P50-NS057531-03, "Cincinnati Center for Neurofibromatosis Research", 7/2008 - 6/2013 (Ratner, PI)

    Children's Tumor Foundation, "Preclinical Testing of Neurofibroma and MPNST", 7/2009 - 6/2011 (Cripe, PI, Ratner, Co-PI)

    U.S. Army NF Program, NF080052, "Therapeutic Targets for Peripheral Nerve Tumors: NF1, NF2, and Schwannomatosis", 3/2009 - 9/2011 (Ratner, PI) 

    U.S. Army NF Program, DOD W81XWH-10-1-0116,  "Modeling the Brain in NF1", 4/2010 - 3/2013 (Ratner, PI)


    Janos Sumegi, MD, PhD

    Professor, UC Department of Pediatrics

    Phone: 513-636-5976

    Fax: 513-636-3549

    Email: janos.sumegi@cchmc.org

    Show All

    Specialties

    Lymphoproliferative disease; hemophagocytic lymphohistiocytosis; usher syndrome

    Education and Training

    MD: University Medical School of Debrecen, Hungary, 1968.

    PhD: Research Center of the Hungarian Academy of Science, Budapest, Hungary, 1974.

    Docent (DMSc): Karolinska Institute Stockhom, Sweden, 1982.

    Publications

    View PubMed Publications

    Grants

    Gene-Expression Profiling of Peripheral Blood Mononuclear Cells in Hemophagocytic Lymphohistiocytosis. Histiocytosis Association of America. Dec 2010 - Nov 2011. 

    A photo of Susanne Wells.

    Susanne Wells, PhD
    Director, Epithelial Carcinogenesis and Stem Cell Program

    513-636-5986

    susanne.wells@cchmc.org

    A photo of Susanne Wells.

    Susanne Wells, PhD

    Director, Epithelial Carcinogenesis and Stem Cell Program

    Director, Postdoctoral Office

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-5986

    Email: susanne.wells@cchmc.org

    Show All

    Specialties

    Squamous cell carcinoma; mechanisms by which the HPV oncogenes subvert the host cell machinery to promote abnormal cell growth and cancer; role of specific cellular HPV targets in viral replication and cellular transformation

    Visit the Wells Lab.

    Biography

    Susanne Wells graduated from the University of Konstanz, Germany, with a degree in Biology. She completed her PhD in Molecular Biology at the State University of Stony Brook, NY, and her Postdoctoral Fellowship at Harvard Medical School, MA. Dr. Wells moved to Cincinnati Children's Hospital Medical Center in 2002 to study human papillomavirus infection and associated carcinogenesis.

    Education and Training

    BS: Biology, University of Konstanz, Germany, 1992.

    PhD: Molecular Genetics, State University of Stony Brook, NY, 1997.

    Postdoctoral Fellowship: Molecular Virology, Harvard Medical School, Boston, MA.

    Publications

    View PubMed Publications

    Grants

    Research Innovation Fund Award
    Title:
    Identification of FA disease biomarkers using NMR-based metabonomics
    PI: Susanne Wells
    Project Period: 2013-2014
    Funding by: Cincinnati Children's Hospital Medical Center


    2R01 CA116316
    Title:
    Role and regulation of the human DEK proto-oncogene
    PI: Susanne Wells
    Project Period: 2012 – 2017
    Funding by: National Institutes of Health

    DOD Idea Award
    Title:
    Targeting the Ron-DEK signaling axis in breast cancer
    PI: Susanne Wells and Susan Waltz
    Project Period: 2012 – 2014
    Funding by: Department of Defense

    2R01 CA102357
    Title:
    Fanconi Anemia and HPV transformation
    PI: Susanne Wells
    Project Period: 2009 – 2014
    Funding by: National Institutes of Health